NCT07224009 2026-03-02
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
University of Arkansas
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT05968690 2025-09-18
Naltrexone and Propranolol Combined With Immunotherapy
Rutgers, The State University of New Jersey
Phase 1 Recruiting
NCT05756764 2025-09-09
Anti-obesity Pharmacotherapy and Inflammation
Louisiana State University Health Sciences Center in New Orleans
Active not recruiting
NCT04499950 2025-03-06
A-NEW
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02137252 2021-11-16
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03581630 2018-08-29
Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients
Gangnam Severance Hospital
Phase NA Completed
NCT00379197 2017-12-28
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01303835 2015-07-17
Low Dose Naltrexone for Glioma Patients
Duke University
Phase 2 Completed
NCT01100437 2012-07-13
Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients
Pfizer
Phase 4 Terminated